Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions

Viral Infections, Non-HIV

Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland

Swiss Med Wkly.

Bachofner J, Valli PV, Bergamin I, Kröger A, Künzler P, Baserga A, Braun DL, Seifert B, Moncsek A, Fehr J, Semela D, Magenta L, Müllhaupt B, Terziroli Beretta-Piccoli B, Mertens J, The Swiss Hepatitis C Cohort Study.

doi: 10.4414/smw.2018.14560.

HIV / AIDS

Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons

AIDS.

Mocroft A, Ryom L, Oprea C, Li Q, Rauch A, Boesecke C, Uzdaviniene V, Sedlacek D, Llibre JM, Lacombe K, Nielsen LN, Florence E, Aho I, Chkhartishvili N, Szlavik J, Dragovic G, Leen C, Sambatakou H, Staub T, Laguno M, Elinav H, Tomažič J, Peters L, EuroSIDA study group.

doi: 10.1097/QAD.0000000000002570.

HIV / AIDSViral Infections, Non-HIV

Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study

Lancet Infect Dis.

Zelenev A, Li J, Mazhnaya A, Basu S, Altice FL

doi: 10.1016/

Viral Infections, Non-HIV

Global prevalence of hepatitis C virus in children in 2018: a modelling study

Lancet Gastroenterol Hepatol.

Schmelzer J, Dugan E, Blach S, Coleman S, Cai Z, DePaola M, Estes C, Gamkrelidze I, Jerabek K, Ma S, Montoya S, Razavi-Shearer D, Razavi-Shearer K, Robbins-Scott S, Razavi H, El Sayed MH

doi: 10.1016/S2468-1253(19)30385-1.

Viral Infections, Non-HIV

Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030

Swiss Med Wkly.

Bruggmann P, Blach S, Deltenre P, Fehr J, Kouyos R, Lavanchy D, Müllhaupt B, Rauch A, Razavi H, Schmid P, Semela D, Stoeckle M, Negro F

doi: 10.4414/smw.2017.14543.

Viral Infections, Non-HIV

Effect of Hepatitis B virus on Steatosis in Hepatitis C virus co-infected subjects: a multi-center study and systematic review

J Viral Hepat.

Goossens N, de Vito C, Mangia A, Clément S, Cenderello G, Barrera F, D'Ambrosio R, Coppola N, Zampino R, Stanzione M, Adinolfi LE, Wedemeyer H, Semmo N, Müllhaupt B, Semela D, Malinverni R, Moradpour D, Heim M, Trincucci G, Rubbia-Brandt , Negro F

doi: 10.1111/jvh.12891.

Further Publications Anesthesiology

Hepatitis C virus elimination in Swiss opioid agonist therapy programmes - the SAMMSU cohort

Swiss Med Wkly

Bregenzer A, Bruggmann P, Castro E, Moriggia A, Rothen M, Thurnheer MC, Vernazza P, Scheidegger C

doi: 10.4414/smw.2021.20460

Further Publications Anesthesiology

Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland

Swiss Med Wkly

Müllhaupt B, Semela D, Ruckstuhl L, Magenta L, Clerc O, Torgler R, Negro F, Semmo N

doi: 10.4414/smw.2021.20399

Viral Infections, Non-HIV

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

Lancet Infect Dis.

Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ

doi: 10.1016/

Related content

Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland

Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons

Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study

Global prevalence of hepatitis C virus in children in 2018: a modelling study

Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030

Effect of Hepatitis B virus on Steatosis in Hepatitis C virus co-infected subjects: a multi-center study and systematic review

Hepatitis C virus elimination in Swiss opioid agonist therapy programmes - the SAMMSU cohort

Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial